Prognostic significance of neutrophil gelatinase-associated lipocalin in St-segment elevation myocardial infarction

Journal of Investigative Medicine

Volumn 60, Issue 2, 2012, Pages 508-513

  Akcay, Adnan Burak ^a   Ozlu, Mehmet Fatih ^b   Sen, Nihat ^a   Cay, Serkan ^b   Ozturk, Oktay Hasan ^a   YalNcn, Fatih ^a   Bilen, Perihan ^a   Kanat, Selcuk ^b   Karakas, Mehmet Fatih ^b   Isleyen, Ahmet ^b   Demir, Ahmet Duran ^b   Sogut, Sadik ^c   Covic, Adrian ^d   Kanbay, Mehmet ^e  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b Yuksek Ihtisas Education and Research Hospital   (Turkey)

^c BEZMIALEM VAKIF UNIVERSITY   (Turkey)

^d GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^e University Hospital ^*  (Turkey)

Author keywords

Neutrophil gelatinaseYassociated lipocalin; Prognosis; ST segment elevation myocardial infarction

Indexed keywords

NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THORAX PAIN;

EID: 84856695896     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e31823e9d86     Document Type: Article

References (31)

1. Cowland JB, Borregaard N. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics. 1997;45(1):17-23. (Pubitemid 27449379)
2. Devarajan P. NGAL in acute kidney injury: from serendipity to utility. Am J Kidney Dis. 2008;52(3):395-399.
3. Bolignano D, Della Torre A, Lacquaniti A, et al. Neutrophil gelatinase-associated lipocalin levels in patients with Crohn disease undergoing treatment with infliximab. J Investig Med. 2010;58(3):569-571.
4. Bolignano D, Donato V, Lacquaniti A, et al. Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Lett. 2010;288(1):10-16.
5. D'Anna R, Baviera G, Giordano D, et al. Neutrophil gelatinase-associated lipocalin serum evaluation through normal pregnancy and in pregnancies complicated by preeclampsia. Acta Obstet Gynecol Scand. 2010;89(2):275-278.
6. Chakraborty S, Kaur S, Muddana V, et al. Elevated serum neutrophil gelatinase-associated lipocalin is an early predictor of severity and outcome in acute pancreatitis. Am J Gastroenterol. 2010;105(9):2050-2059.
7. Gupta K, Shukla M, Cowland JB, et al. Neutrophil gelatinase-associated lipocalin is expressed in osteoarthritis and forms a complex with matrix metalloproteinase 9. Arthritis Rheum. 2007;56(10):3326-3335. (Pubitemid 47585427)
8. Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease. Scand J Clin Lab Invest Suppl. 2008;241:89-94. (Pubitemid 351883665)
9. Aghel A, Shrestha K, Mullens W, et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail. 2010;16(1):49-54.
10. Ding L, Hanawa H, Ota Y, et al. Lipocalin-2/neutrophil gelatinase-B associated lipocalin is strongly induced in hearts of rats with autoimmune myocarditis and in human myocarditis. Circ J. 2010;74(3):523-530.
11. Alvelos M, Pimentel R, Pinho E, et al. Neutrophil gelatinase-associated lipocalin in the diagnosis of type 1 cardio-renal syndrome in the general ward. Clin J Am Soc Nephrol. 2011;6(3):476-481.
12. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54(23):2129-2138.
13. Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2008;51(2):210-247.
14. Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 2003;349(8):733-742. (Pubitemid 37010777)
15. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102(17):2031-2037.
16. Schroder R. Prognostic impact of early ST-segment resolution in acute ST-elevation myocardial infarction. Circulation. 2004;110(21):e506-e510.
17. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344-2351. (Pubitemid 46685903)
18. Hemdahl AL, Gabrielsen A, Zhu C, et al. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol. 2006;26(1):136-142. (Pubitemid 43732240)
19. Bu DX, Hemdahl AL, Gabrielsen A, et al. Induction of neutrophil gelatinase-associated lipocalin in vascular injury via activation of nuclear factor-kappa B. Am J Pathol. 2006;169(6):2245-2253. (Pubitemid 351181982)
20. Leclercq A, Houard X, Philippe M, et al. Involvement of intraplaque hemorrhage in atherothrombosis evolution via neutrophil protease enrichment. J Leukoc Biol. 2007;82(6):1420-1429. (Pubitemid 350276953)
21. Reape TJ, Groot PH. Chemokines and atherosclerosis. Atherosclerosis. 1999;147(2):213-225. (Pubitemid 29512252)
22. Mariani M, Fetiveau R, Rossetti E, et al. Significance of total and differential leucocyte count in patients with acute myocardial infarction treated with primary coronary angioplasty. Eur Heart J. 2006;27(21):2511-2515. (Pubitemid 44627292)
23. Mueller C, Buettner HJ, Hodgson JM, et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation. 2002;105(12):1412-1415. (Pubitemid 34263269)
24. Hoffmann R, Suliman H, Haager P, et al. Association of C-reactive protein and myocardial perfusion in patients with ST-elevation acute myocardial infarction. Atherosclerosis. 2006;186(1):177-183.
25. Elneihoum AM, Falke P, Hedblad B, et al. Leukocyte activation in atherosclerosis: correlation with risk factors. Atherosclerosis. 1997;131(1):79-84. (Pubitemid 27240100)
26. Elneihoum AM, Falke P, Axelsson L, et al. Leukocyte activation detected by increased plasma levels of inflammatory mediators in patients with ischemic cerebrovascular diseases. Stroke. 1996;27(10):1734-1738. (Pubitemid 26332495)
27. Anwaar I, Gottsater A, Ohlsson K, et al. Increasing levels of leukocyte-derived inflammatory mediators in plasma and cAMP in platelets during follow-up after acute cerebral ischemia. Cerebrovasc Dis. 1998;8(6):310-317. (Pubitemid 28491091)
28. Falke P, Elneihoum AM, Ohlsson K. Leukocyte activation: relation to cardiovascular mortality after cerebrovascular ischemia. Cerebrovasc Dis. 2000;10(2):97-101. (Pubitemid 30107503)
29. Zografos T, Haliassos A, Korovesis S, et al. Association of neutrophil gelatinase-associated lipocalin with the severity of coronary artery disease. Am J Cardiol. 2009;104(7):917-920.
30. Yndestad A, Landro L, Ueland T, et al. Increased systemic andmyocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J. 2009;30(10):1229-1236.
31. Bolignano D, Basile G, Parisi P, et al. Increased plasma neutrophil gelatinase-associated lipocalin levels predict mortality in elderly patients with chronic heart failure. Rejuvenation Res. 2009;12(1):7-14.